<img src="https://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7?size=2" nborder="0" align="left" hspace="5" vspace="5" title="22157.jpg" alt="Company Logo"/>The main market opportunities lie in PSMA-targeted therapies and radiodiagnostics, which are proving commercially successful for PET imaging and treatment of prostate cancer. Growth potential exists in radioligand therapies and PSMA-targeted approaches using various payloads for advanced prostate cancer treatment.Dublin, May 14, 2026 (GLOBE NEWSWIRE) -- The <a href="https://www.researchandmarkets.com/reports/6179369/competitor-analysis-psma-targeted-therapy-and?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=33j72w&amp;utm_campaign=2252534+-+PSMA-Targeted+Therapy+%26+Radiodiagnostics+Pipeline+Competitor+Analysis+Report+2026%3a+Active+R%26D+Programs+by+R%26D+Phase+and+Profile+of+Targeted+Therapies+or+Radio-diagnostics+by+Drug+Modality&amp;utm_exec=chdomspi" rel="nofollow" target="_blank" title="Competitor Analysis: PSMA-Targeted Therapy &amp; Radiodiagnostics">"Competitor Analysis: PSMA-Targeted Therapy &amp; Radiodiagnostics"</a> report has been added to ResearchAndMarkets.com's offering. This competitive intelligence report about PSMA-Targeted Therapies &amp; Radiodiagnostics provides a competitor evaluation in the field of product candidates in research and development targeting prostate-specific membrane antigen (PSMA). This report will be prepared on demand within one working day upon order placement. The report lists PSMA-targeted R&amp;D programs by R&amp;D phase in a tabular format and describes in brief the profile of PSMA-targeted therapies or radio-diagnostics by drug modality. PSMA-targeting is a clinically validated and increasingly commercially successful approach for positron emission tomography (PET) of prostate cancer and for treatment of PSMA-positive metastatic castration-resistant prostate cancer: <ul><li>With 2024 sales of US$ 1,058 mln (+24.3% vs 2023), the fluorinated PSMA-targeted PET imaging agent PYLARIFY exceeds US$ 1 billion in net sales and became the first ever blockbuster radiodiagnostic.</li><li>PLUVICTO (lutetium Lu 177 vipivotide tetraxetan) is a radioligand therapeutic agent. Lutetium Lu 177 vipivotide tetraxetan is a PSMA-binding ligand bound to a DOTA chelator radiolabeled with lutetium-177. Pluvicto posted 2024 sales of US$ 1,392 mln (+42% vs 2023).</li></ul> Prostate specific membrane antigen (PSMA) expression is prevalent in prostate cancer, preserved during malignant transformation, and increases in response to anti-androgen therapies, making it a commonly targeted tumor associated antigen for prostate cancer. PSMA mainly serves as a binding target for delivery of a variety of payloads, including, but not limited to, cytotoxic drugs in antibody-drug conjugates, recruitment of cytotoxic T-cells in bispecific antibodies or directly PSMA-targeted chimeric antigen receptor T-cells or natural killer cells. PSMA is also an important binding target for delivery of radioactive payloads in targeted radioligand therapy, whereby binding molecules can be small molecules, peptides and antibodies. A variety of radioligands are being evaluated or have already been approved, including lutetium 177, actinium 225, lead 212, cupper 67, terbium 161, and astatine 211. For more information about this report visit <a href="https://www.researchandmarkets.com/reports/6179369/competitor-analysis-psma-targeted-therapy-and?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=33j72w&amp;utm_campaign=2252534+-+PSMA-Targeted+Therapy+%26+Radiodiagnostics+Pipeline+Competitor+Analysis+Report+2026%3a+Active+R%26D+Programs+by+R%26D+Phase+and+Profile+of+Targeted+Therapies+or+Radio-diagnostics+by+Drug+Modality&amp;utm_exec=chdomspi" rel="nofollow" target="_blank" title="">https://www.researchandmarkets.com/r/kwu7w0</a> About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. <pre>CONTACT: 
CONTACT: ResearchAndMarkets.com 
 Laura Wood,Senior Press Manager 
 press@researchandmarkets.com
 For E.S.T Office Hours Call 1-917-300-0470 
 For U.S./ CAN Toll Free Call 1-800-526-8630 
 For GMT Office Hours Call +353-1-416-8900 

</pre> <img alt="" src='https://ml.globenewswire.com/media/ZjljZTBkZGQtNzkwYi00OTQ2LWI2MTItMDViZmRkMjE4Yzg3LTEwMjY3MzctMjAyNi0wNS0xNC1lbg==/tiny/Research-and-Markets.png' referrerpolicy='no-referrer-when-downgrade' />

GlobeNewswire Inc.

PSMA-Targeted Therapy & Radiodiagnostics Pipeline Competitor Analysis Report 2026: Active R&D Programs by R&D Phase and Profile of Targeted Therapies or Radio-diagnostics by Drug Modality

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn